Aberdeen Group
ABVX

Aberdeen Group’s Abivax ABVX Stock Holding History

Aberdeen Group’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.6M Buy
522,025
+90,784
+21% +$10.3M 0.1% 165
2026
Q1 		$48M Buy
431,241
+4,583
+1% +$542K 0.08% 222
2025
Q4 		$57.5M Sell
426,658
-360,759
-46% -$39.4M 0.09% 181
2025
Q3 		$66.9M Buy
787,417
+76,901
+11% +$4.71M 0.11% 159
2025
Q2 		$5.44M Hold
710,516
– – 0.01% 695
2025
Q1 		$4.44M Buy
710,516
+286,335
+68% +$1.94M 0.01% 693
2024
Q4 		$3.11M Buy
424,181
+107,750
+34% +$992K 0.01% 711
2024
Q3 		$3.65M Buy
316,431
+198,225
+168% +$2.38M 0.01% 698
2024
Q2 		$1.56M Buy
+118,206
New +$1.69M ﹤0.01% 781

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aberdeen Group's ABVX Position: Q2 2026 in Review

Aberdeen Group increased its Abivax (ABVX) stake by 21% in Q2 2026, buying an estimated $10.3M and bringing the position to 522,025 shares worth $69.6M. The position accounts for 0.1% of the portfolio, ranked #165.

Aberdeen Group first reported a position in ABVX in Q2 2024 and has held it in 9 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Aberdeen Group held 522,025 shares of Abivax worth $69.6M as of Q2 2026.
  • Aberdeen Group bought 90,784 Abivax shares in Q2 2026, an estimated $10.3M.
  • Abivax made up 0.1% of Aberdeen Group's portfolio in Q2 2026, its #165 holding.
  • Aberdeen Group first reported a position in Abivax in Q2 2024 and has held it in 9 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.